Testimony

FDA Meeting – Osteoporosis Drug Development

By Christina Cherel | Nov 4, 2015 | Comments Off on FDA Meeting – Osteoporosis Drug Development

Food and Drug Administration Meeting of the Division of Bone, Reproductive, and Urologic Products in the Center for Drug Evaluation and Research.

FDA Meeting – Essure

By Cindy Pearson | Sep 24, 2015 | Comments Off on FDA Meeting – Essure

Testimony Delivered at the FDA Meeting of the Obstetrics and Gynecology Devices Panel

FDA Meeting – Generic Drug Labeling

By Coco Jervis | Mar 27, 2015 | Comments Off on FDA Meeting – Generic Drug Labeling

Statement of Coco Jervis, J.D., Program Director |
Food and Drug Administration Public Meeting on Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products

FDA Scientific Workshop – Female Sexual Interest/Arousal Disorder

By Cindy Pearson | Oct 28, 2014 | Comments Off on FDA Scientific Workshop – Female Sexual Interest/Arousal Disorder

Food and Drug Administration Scientific Workshop on Female Sexual Interest/Arousal Disorder

FDA Meeting – Lorcaserin

By Kate Ryan | May 10, 2012 | Comments Off on FDA Meeting – Lorcaserin

Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Meeting on Lorcaserin

FDA Meeting – Qnexa Safety and Efficacy

By Kate Ryan | Feb 22, 2012 | Comments Off on FDA Meeting – Qnexa Safety and Efficacy

Food and Drug Administration’s (FDA) Endocrinologic and Metabolic Drugs Advisory Committee Meeting

FDA Meeting – Naltrexone/Bupropion (Contrave)

By Kate Ryan | Dec 7, 2010 | Comments Off on FDA Meeting – Naltrexone/Bupropion (Contrave)

Food and Drug Administration (FDA) Gastroenterology Endocrinologic and Metabolic Drugs Advisory Committee